Issue Date: January 4, 2016
ACS Award For Team Innovation: Matthew F. Brown, Paul S. Changelian, Mark E. Flanagan, Michael J. Munchhof, and Chakrapani Subramanyam
Sponsor: ACS Corporation Associates
Citation: For work leading to the invention of Xeljanz (tofacitinib), the first JAK inhibitor to be approved for the treatment of rheumatoid arthritis.
What their colleagues say: “I sincerely believe that their landmark discovery of the first successful JAK inhibitor as an oral medicine for the treatment of rheumatoid arthritis is a dramatic medical advance, which will benefit countless humans for many years to come. I have followed this field and . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society